Role of prophylactic vitamin K in preventing antibiotic induced hypoprothrombinemia

Farookh Aziz1, Prashant Patil

  • 1Department of Pediatrics, Govt. Medical College, Aurangabad, Maharashtra, India, afarookh@rediffmail.com.

Insights

A single prophylactic dose of vitamin K does not prevent antibiotic-induced hypoprothrombinemia in critically ill children. Vitamin K deficiency remains common in these patients, regardless of prophylactic treatment.

Area of Science:

  • Pediatric critical care medicine
  • Pharmacology
  • Nutritional science

Background:

  • Antibiotic therapy can lead to hypoprothrombinemia due to vitamin K deficiency.
  • Critically ill children are at risk for prolonged antibiotic use and potential complications.

Purpose of the Study:

  • To evaluate the prophylactic efficacy of a single vitamin K dose in preventing antibiotic-induced hypoprothrombinemia.
  • To assess the incidence of vitamin K deficiency in critically ill children receiving prolonged antibiotics.

Main Methods:

  • Prospective comparative study of 120 critically ill children (2 mo–12 y).
  • Group A received prophylactic vitamin K; Group B did not.
  • Coagulation studies were monitored on days 10 and 14; therapeutic vitamin K was administered if INR deranged.

Main Results:

  • Vitamin K deficiency occurred in 15% of children on prolonged antibiotics.
  • Incidence of deficiency was similar in both prophylactic and non-prophylactic groups (p=0.79).
  • Risk factors included male sex, severe protein energy malnutrition, NMTT-containing antibiotics, and >10 days of antibiotic use.

Conclusions:

  • Vitamin K deficiency is a significant issue in critically ill children on prolonged antibiotic therapy.
  • A single prophylactic dose of vitamin K is ineffective in preventing antibiotic-induced hypoprothrombinemia.
Abstract

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
481
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
257
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
665